Low-carb diets, fasting and euphoria:: Is there a link between ketosis, and γ-hydroxybutyrate (GHB)?

被引:23
作者
Brown, Andrew J. [1 ]
机构
[1] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia
关键词
D O I
10.1016/j.mehy.2006.07.043
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Anecdotal evidence Links the initial phase of fasting or a low-carbohydrate diet with feelings of well-being and mild euphoria. These feelings have often been attributed to ketosis, the production of ketone bodies which can replace glucose as an energy source for the brain. One of these ketone bodies, P-hydroxybutyrate (BHB), is an isomer of the notorious drug of abuse, GHB (gamma-hydroxybutyrate). GHB is also of interest in relation to its potential as a treatment for alcohol and opiate dependence and narcolepsy-associated cataplexy. Here I hypothesize that, the mild euphoria often noted with fasting or low-carbohydrate diets may be due to shared actions of BHB and GHB on the brain. Specifically, I propose that BHB, like GHB, induces mild euphoria by being a weak partial agonist for GABA(B) receptors. I outline several approaches that would test the hypothesis, including receptor binding studies in cultured cells, perception studies in trained rodents, and psychometric testing and functional magnetic resonance imaging in humans. These and other studies investigating whether BHB and GHB share common effects on brain chemistry and mood are timely and warranted, especially when considering their structural similarities and the popularity of ketogenic diets and GHB as a drug of abuse. (c) 2006 Elsevier Ltd. ALL rights reserved.
引用
收藏
页码:268 / 271
页数:4
相关论文
共 20 条
[1]   Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) and its metabolic precursor, gamma-butyrolactone (GBL) in rats [J].
Baker, LE ;
Van Tilburg, TJ ;
Brandt, AE ;
Poling, A .
PSYCHOPHARMACOLOGY, 2005, 181 (03) :458-466
[2]   GHB (γ-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier [J].
Bhattacharya, I ;
Boje, KMK .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :92-98
[3]  
BLOOM WL, 1959, METABOLISM, V8, P214
[4]   Unravelling the brain targets of γ-hydroxybutyric acid [J].
Crunelli, V ;
Ernri, Z ;
Leresche, N .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (01) :44-52
[5]   Is there an astrocyte-neuron ketone body shuttle? [J].
Guzmán, M ;
Blázquez, C .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2001, 12 (04) :169-173
[6]   D-β-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease [J].
Kashiwaya, Y ;
Takeshima, T ;
Mori, N ;
Nakashima, K ;
Clarke, K ;
Veech, RL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5440-5444
[7]  
KERNDT PR, 1982, WESTERN J MED, V137, P379
[8]   D-β-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures [J].
Masuda, R ;
Monahan, JW ;
Kashiwaya, Y .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 80 (04) :501-509
[9]   Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABA(B) receptor agonist [J].
Mathivet, P ;
Bernasconi, R ;
DeBarry, J ;
Marescaux, C ;
Bittiger, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (01) :67-75
[10]   HYPOTHALAMIC NEURONAL-ACTIVITY RESPONSES TO 3-HYDROXYBUTYRIC ACID, AN ENDOGENOUS ORGANIC-ACID [J].
MINAMI, T ;
SHIMIZU, N ;
DUAN, S ;
OOMURA, Y .
BRAIN RESEARCH, 1990, 509 (02) :351-354